Elena Fisheleva
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model.
Journal: Clinical pharmacokinetics
Published: March 14, 2024
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
Journal: The Lancet. Child & adolescent health
Published: April 06, 2023
Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational study.
Journal: Genetics in medicine : official journal of the American College of Medical Genetics
Published: May 26, 2022
Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.
Journal: Clinical pharmacokinetics
Published: July 11, 2021
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Journal: Genetics in medicine : official journal of the American College of Medical Genetics
Published: May 01, 2021
Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery.
Journal: Science progress
Published: March 25, 2021
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
Journal: Lancet (London, England)
Published: April 24, 2020
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study.
Journal: The Lancet. Rheumatology
Published: December 20, 2019
MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study.
Journal: The Lancet. Rheumatology
Published: December 20, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026